XNASACLX
Market cap3.91bUSD
Jan 10, Last price
69.08USD
1D
-6.22%
1Q
-12.83%
IPO
305.04%
Name
Arcellx Inc
Chart & Performance
P/E
—
P/S
33.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
210.85%
Rev. gr., 5y
%
Revenues
110m
Net income
-71m
L-62.01%
CFO
208m
P
Profile
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 110,319 | |||||
Cost of revenue | 200,199 | 193,483 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (89,880) | (193,483) | ||||
NOPBT Margin | ||||||
Operating Taxes | 663 | (2,580) | ||||
Tax Rate | ||||||
NOPAT | (90,543) | (190,903) | ||||
Net income | (70,690) -62.01% | (186,099) 191.11% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 299,706 | 259,833 | ||||
BB yield | -11.24% | -19.02% | ||||
| Debt | ||||||
Debt current | 47,754 | 35,961 | ||||
Long-term debt | 148,466 | 140,301 | ||||
Deferred revenue | 170,673 | |||||
Other long-term liabilities | ||||||
Net debt | (532,965) | (81,074) | ||||
| Cash flow | ||||||
Cash from operating activities | 207,573 | (99,303) | ||||
CAPEX | (21,428) | (2,277) | ||||
Cash from investing activities | (154,512) | (117,674) | ||||
Cash from financing activities | 279,163 | 252,625 | ||||
FCF | (120,480) | (220,475) | ||||
| Balance | ||||||
Cash | 702,017 | 254,835 | ||||
Long term investments | 27,168 | 2,501 | ||||
Excess cash | 723,669 | 257,336 | ||||
Stockholders' equity | (388,881) | (318,967) | ||||
Invested Capital | 1,142,559 | 612,052 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 48,061 | 44,106 | ||||
Price | 55.50 79.15% | 30.98 | ||||
Market cap | 2,667,410 95.21% | 1,366,403 | ||||
EV | 2,134,445 | 1,285,329 | ||||
EBITDA | (87,840) | (192,162) | ||||
EV/EBITDA | ||||||
Interest | 3,842 | 1,720 | ||||
Interest/NOPBT | ||||||